• 中国资本市场开放出大招 跨境证券投资更便利 2019-10-13
  • 世卫将“游戏障碍”列为新疾病 哪些症状可被确诊? 2019-10-13
  • 景区去门票化积弊短期难除 如何摆脱门票依赖? 2019-10-08
  • 东风路老旧小区欲华丽变身 微改造项目勘察设计已招标 ——凤凰网房产广州 2019-10-08
  • 翔龙无人机服役后首次曝光,大幅提升空军情报收集能力 2019-09-19
  • 证监会去年对外公开监管信息14560条 2019-09-19
  • 人民网欧洲中心分社记者报道集 2019-09-06
  • 图解:短视频平台频遭约谈敲响警钟,野蛮生长要不得! 2019-09-06
  • 中考期间广州部分公交线路有调整 2019-09-01
  • 减肥必备!这十种食物饱口福还能吃出好身材 2019-09-01
  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置时时彩网络平台>技术资料首页>行业动态>新品动态>Biomarin Pharm:FDA受理vimizim BLA

    江苏快3大小单双玩法技巧: Biomarin Pharm:FDA受理vimizim BLA

    互联网2013年5月31日 14:00 点击:1345

    时时彩网络平台 www.qlgr.net 美国BioMarin Pharmaceutical

    Biomarin Pharm宣布,美国FDA受理公司commit的Vimizim生物制剂申请(BLA),Vimizim为根据评估患者的治疗IVA型酶罕见溶酶体贮积症粘多醣(MPS IVA)替代疗法。

     

    May 30, 2013

    FDA Accepts Vimizim BLA and Grants Priority Review Designation

    PDUFA Action Date Extended to February 28, 2014

     

    SAN RAFAEL, Calif., May 30, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for Vimizim (BMN-110, elosulfase alfa), an enzyme replacement therapy under evaluation for the treatment of patients with the rare lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), also called Morquio A Syndrome.

    The FDA has granted priority review designation to Vimizim, which is granted to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. During the initial review of the application, the FDA requested additional Chemistry, Manufacturing and Controls (CMC) information. The company provided the information as requested, and the FDA designated it as a major amendment to the application thus extending the PDUFA action date by three months. The extended PDUFA action date is February 28, 2014. 

    In the FDA's filing communication, the Agency informed the company that it is currently planning to hold an advisory committee meeting to discuss the application. No date has been set for this meeting. 

    "We are pleased that the FDA has granted priority review to the Vimizim BLA, and we look forward to a productive dialog with the FDA as they review the application," said Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin. "With our expertise in developing enzyme replacement therapies to treat serious unmet medical needs, we plan to work closely with the FDA and other regulatory authorities to bring this much needed therapy to MPS IVA patients worldwide."

    About MPS IVA

    Mucopolysaccharidosis IVA (MPS IVA, also known as Morquio A Syndrome) is a disease characterized by deficient activity of N-acetylgalactosamine-6-sulfatase (GALNS) causing excessive lysosomal storage of glycosaminoglycans such as keratan sulfate and chondroitin sulfate. This excessive storage causes a systemic skeletal dysplasia, short stature, and joint abnormalities, which limit mobility and endurance. Malformation of the chest impairs respiratory function, and looseness of joints in the neck cause spinal instability and potentially spinal cord compression. Other symptoms may include hearing loss, corneal clouding, and heart disease. Initial symptoms often become evident in the first five years of life. The disease substantially limits both the quality and length of life of those affected.

    The rate of incidence of MPS IVA is as yet unconfirmed and varies among different populations but estimates vary between 1 in 200,000 live births and 1 in 250,000 live births. The estimated prevalence is approximately 3,000 patients in the developed world. Based on knowledge of the worldwide distribution of the MPS VI market and the more than 1,300 identified MPS IVA patients worldwide, the company estimates that approximately 20 percent of patients are in North America (15 percent in the U.S.) and approximately 50 percent of patients are in EUMEA. 

    About BioMarin

    BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include BMN-110 (elosulfase alfa), formally referred to as GALNS, which successfully completed Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers, and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

    (来源: 互联网 )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, 时时彩网络平台,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


  • 中国资本市场开放出大招 跨境证券投资更便利 2019-10-13
  • 世卫将“游戏障碍”列为新疾病 哪些症状可被确诊? 2019-10-13
  • 景区去门票化积弊短期难除 如何摆脱门票依赖? 2019-10-08
  • 东风路老旧小区欲华丽变身 微改造项目勘察设计已招标 ——凤凰网房产广州 2019-10-08
  • 翔龙无人机服役后首次曝光,大幅提升空军情报收集能力 2019-09-19
  • 证监会去年对外公开监管信息14560条 2019-09-19
  • 人民网欧洲中心分社记者报道集 2019-09-06
  • 图解:短视频平台频遭约谈敲响警钟,野蛮生长要不得! 2019-09-06
  • 中考期间广州部分公交线路有调整 2019-09-01
  • 减肥必备!这十种食物饱口福还能吃出好身材 2019-09-01
  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 十三水摆牌注意点 北京pk10开始直播 查看广西快乐双彩走势图 河南福彩一幸运武林走势图 11选五多乐彩走势图 百家乐开发软件 浙江20选5杀号 彩票杀号规律计算公式 北单论坛 赛马会net 福彩3d位选投注金额表 余额宝是稳赚不赔吗 如何在网上开彩票投注站 下载河南快三助手 体彩p5软件